Our Experiences by 2016

45 views

Published on

  • Be the first to comment

  • Be the first to like this

Our Experiences by 2016

  1. 1. “Spectrum” of Services
  2. 2. Oncology Experience Indication Imaging Modalities # ofStudies # ofPatientsPh I Ph II Ph III Ph IV BladderCancer CT, MRI, XR, Bone 2 1 1,100 Breastcancer CT, MRI, XR 1 4 7 3,600 ChronicLymphocyticLeukemia CT, MRI, PET 2 2 4 1,500 Colon CT, MRI, PET 3 1 2,200 Colorectal CT, MRI, PET 3 2 700 Diffuse Large B-Cell Lymphoma CT, MRI, PET 2 1 500 Esophagus CT, MRI, PET 1 200 FollicularLymphoma CT, MRI, PET 2 700 Gastric Cancer CT 1 3 2,300 HCC CT, MRI 3 1 800 Head& Neck CT, MRI, PET 3 1 340 Mantle Cell Lymphoma CT, MRI, PET 1 2 320 Melanoma CT, MRI, PET 2 3 4 3,800 Multiple Myeloma MRI 1 70 Non-HodgkinsLymphoma CT, MRI, PET 1 6 7 3,900 Non-Small Cell LungCancer CT, MRI, XR, Bone 3 8 3,600 Ovarian CT, MRI 3 4 2,600 Pancreatic CT, MRI, XR 1 3 1 1,400 Prostate Cancer CT, MRI, XR, Bone 1 5 6 7,000 RCC MRI, PET 1 1 900 Sarcoma CT, MRI 1 1 500 SolidTumors CT, MRI 2 75
  3. 3. Other Therapeutic Areas CNS Phases # ofsites # ofpatients Modalities Multiple Sclerosis II,III 40-160 10-1,500 MR SubarachnoidHemorrhage III 100-150 750-1,500 CT, DSA,CTA MSK Phases # ofsites # ofpatients Modalities Osteoporosis I, II,III 1-400 12-17,000 X-Ray,DXA RheumatoidArthritis I, II,III 1-80 10-1,500 X-Ray,MRI Osteoarthritis I, II,III 1-350 12-2,250 X-Ray,MRI Cardiology Phases # ofsites # ofpatients Modalities Peripheral Arterial Occlusion III 90 100 Arteriograms Fabry Disease II,III 2 60 Echo Heart Failure III 40 600 Echo Atrial Fibrillation Pivotal Device 25 220 CTA,TEE, CT, MR EisenmengerSyndrome III 90 220 PA,CTPA,MRA, Echo Pulmonary Phases # ofsites # ofpatients Modalities Arterial Hypertension IV 30 100 PET, cMRI, 3D Echo ChronicThromboembolicHypertension II 60 150 PA,CTPA,MRA, V/Q Imaging Agents Phases # ofsites # ofpatients Modalities Vascular III 15-25 35-300 MRA, DSA Renal III 25 330 MRI Oncology I, III 1 30-140 CT, PET-CT,SPECT-CT
  4. 4. Immunotherapy Experience Phase Indication Agent Type Criteria Endpoint # of sites # of subjects III NSCLC Vaccine therapy RECIST 1.1 ProgressionFree Survival (PFS) 89 506 III Non-Hodgkin’s Lymphoma Autologoustumorderived immunoglobulinidiotypevaccine Cheson Disease Free Survival (DFS) 30 650 III MetastaticMelanoma Oncolyticviral vaccine therapy ModifiedirRC Durable Response Rate 75 400 II MetastaticMelanoma Monoclonal antibody irRC & RECIST 1.1 PFS 31 100 I Hepatocellular Carcinoma Intralesionalinjection RECIST 1.1 PFS 2 45 III Colon Autologoustumorcell immunotherapy RECIST 1.1 DFS 40 550 II Ovarian Autologoustumorcell immunotherapy RECIST 1.1 Recurrence-FreeSurvival 80 400 III LocallyAdvanced CutaneousMelanoma Intralesionalinjection RECIST 1.1 PFS 30 225 III MetastaticMelanoma Oncolyticviral vaccine therapy/anti-PD-1monoclonal antibody Modified irRECIST& RECIST PFS 150 800

×